Hlh Case Study

1. Henter J.I., Horne A., Aricó M., Egeler M., Filipovich A., Imashuku S. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–131.[PubMed]

2. Henter J.I., Elinder G., Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. the FHL study group of the histiocyte society. Semin Oncol. 1991;18(1):29–33.[PubMed]

3. Fishman D.N. Hemophagocytic syndromes and infection. Emerg Infect Dis. 2000;6:601–608.[PubMed]

4. Reiner A.P., Spivak J.L. Hematophagic histiocytosis. A report of 23 new patients and a review of the literature. Medicine (Baltimore) 1988;67(6):369–388.[PubMed]

5. George M.R. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med. 2014;5:69–86.[PubMed]

6. Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L. The global distribution and burden of dengue. Nature. 2013;496:504–507.[PubMed]

7. Bandyopadhyay B., Bhattacharyya I., Adhikary S., Konar J., Dawar N., Sarkar J. A comprehensive study on the 2012 dengue fever outbreak in Kolkata, India. ISRN Virol. 2013;7:5.

8. De Koninck A.S., Dierick J., Steyaert S., Taelman P. Hemophagocytic lymphohistiocytosis and dengue infection: rare case report. Acta Clin Belg. 2014;69(3):210–213.[PubMed]

9. Tan L.H., Lum L.C.S., Omar S.F.S., Kan F.K. Hemophagocytosis in dengue: comprehensive report of six cases. J Clin Virol. 2012;55(1):79–82.[PubMed]

10. Mitra S., Bhattacharyya R. Hemophagocytic syndrome in severe dengue fever: a rare presentation. Indian J Hematol Blood Transfus. 2014;30(1):97–100.[PMC free article][PubMed]

11. Wan Jamaludin W.F., Periyasamy P., Wan Mat W.R., Abdul Wahid S.F. Dengue infection associated hemophagocytic syndrome: therapeutic interventions and outcome. J Clin Virol. 2015;69:91–95.[PubMed]

12. Sharp T.M., Gaul L., Muehlenbachs A., Hunsperger E., Bhatnagar J., Lueptow R. Fatal hemophagocytic lymphohistiocytosis associated with locally acquired dengue virus infection – New Mexico and Texas, 2012. MMWR Morb Mortal Wkly Rep. 2014;63(3):49–54.[PubMed]

13. Srichaikul T., Punyagupta S., Kanchanapoom T., Chanokovat C., Likittanasombat K., Leelasiri A. Hemophagocytic syndrome in Dengue hemorrhagic fever with severe multiorgan complications. J Med Assoc Thai. 2008;91(1):104–109.[PubMed]

14. Jain D., Singh T. Dengue virus related hemophagocytosis: a rare case report. Hematology. 2013;13:286–288.[PubMed]

15. Lu P.L., Hsiao H.H., Tsai J.J., Chen T.C., Feng M.C., Chen T.P. Dengue virus-associated hemophagocytic syndrome and dyserythropoiesis: a case report. Kaohsiung J Med Sci. 2005;21:34–39.[PubMed]

16. Raju S., Kalyanaraman S., Swaminathan K., Nisha A., Praisid S. Hemophagocytic lymphohistiocytosis syndrome in Dengue hemorrhagic fever. Indian J Pediatr. 2014;81(12):1381–1383.[PubMed]

Introduction

Hemophagocytic lymphohistiocytosis (HLH) is an immune hyperactivation syndrome characterized by clinical signs and symptoms of severe uncontrolled inflammation.1

Diagnosis is based on combined clinical, laboratory, genetic, and morphological criteria. According to the Histiocyte Society,2 in the absence of family history or of specific genetic tests, five out of eight criteria must be present in order to establish a diagnosis and initiate treatment (Table 1).

Table 1 Criteria for the diagnosis of hemophagocytic lymphohistiocytosis. 

  1. Molecular diagnosis compatible with hemophagocytic lymphohistiocytosis

    OR

  2. At least five out of the eight following criteria:

    1. Fever

    2. Splenomegaly

    3. Cytopenias (two or more lineages)

      • - Hemoglobin <9 g/dL or <10 g/dL in newborn babies

      • - Platelets <100 × 109/L

      • - Neutrophils <1.0 × 109/L

    4. Hypertriglyceridemia (>265 mg/dL) or hypofibrinogenemia (<150mg/dL)

    5. Hemophagocytosis in bone marrow, spleen, lymph nodes or liver without any evidence of malignancy

    6. Decreased or absent activity of natural killer cells

    7. Serum ferritin >500μg/L

    8. Increased soluble CD25 (>2400 U/mL)

Modified from Henter et al.2

Common findings in HLH include persistent fever, hep-atosplenomegaly, cytopenia, decreased activity of cytotoxic T lymphocytes and natural killer cells (NK), as well as widespread accumulation of lymphocytes and macrophages that carry out hemophagocytosis.3

HLH is included in the differential diagnosis of a number of diseases commonly found in children, such as autoimmune diseases, primary immunodeficiencies, malignancies, and infectious diseases.3

There are two main forms, primary or familial HLH and secondary HLH. Secondary HLH can be associated with infections, autoimmune disorders or malignancies. Despite attempts to differentiate between primary and secondary forms of HLH, their clinical features are very similar.4,5

Remission may be achieved in primary HLH with immunochemotherapy and in cases of secondary HLH by treating the underlying disease.68 However, all patients with the familial form of HLH relapsed or died until treatment using allogeneic bone marrow transplantation (BMT) started to be used.2,6

Given its rarity and the scarcity of data in the Brazilian literature, this retrospective study was carried out to describe the clinical and laboratory presentation of HLH in children followed at the Hematology Service of the Hospital das Clini-cas, Universidade Federal de Minas Gerais (HC-UFMG) between January 2010 and July 2012.

The study was approved by the Institution's Research Ethics Committee (protocol no. 05683012.9.0000.5149), and patients and guardians were asked to sign informed consent forms.

Case report

Seven children were included. Age at diagnosis ranged from one month to nine years, with a median of 13 months. All patients presented with splenomegaly and fever. Other clinical manifestations are shown in Table 2. Only one case (#7) had a family history suggesting HLH.

Table 2 Clinical and laboratorial characteristics of seven children with hemophagocytic lymphohistiocytosis (HLH). 

#GenderAge at diagnosisEnlarged lymph nodesCutaneous rashJaundiceFibrinogen (mg/dL)Hemophagocytosis in bone marrowSpinal fluid examInfections and associated diseasesType of immunochemotherapy/present clinical status
1F5 monthNoNoYes89NoNDVisceral leishmaniasisND/Alive in remission
2M13 monthsNoNoNo>400YesPleocytosisEpstein-Barr virusHLH 2004/Bone marrow transplantation in July 2012; alive in remission
3M5 monthsNoNoNo97YesNDVisceral leishmaniasisND/Alive in remission
4M16 monthsYesYesYes131YesNDCytomegalovirusHLH 1994/No remission. Death after sepsis
5M3 yearsYesNoYes59YesNDEpstein-Barr virusHLH 1994/Alive in remission
6F9 yearsNoYesYes94YesPleocytosisEpstein-Barr virus/Juvenile Rheumatoid ArthritisHLH 2004/Alive in remission
7M1 monthNoNoNo35YesNDNone provenND/Death after 48 h from hospital admission

F: female; M: male; ND: not done.

All children had anemia, thrombocytopenia, hypertriglyceridemia, and hyperferritinemia at the time of diagnosis. Hypofibrinogenemia was observed in six cases (85.7%). Hemophagocytosis features were visible in the bone marrows of six patients (85.7%) at diagnosis (Table 2). Lumbar puncture with cerebrospinal fluid (CSF) analysis was performed in two cases; both had pleocytosis. Cranial computed tomography was performed in one patient (#4) which revealed diffuse cortical atrophy.

The estimated time between the onset of symptoms and HLH diagnosis ranged from 10 to 60 days (median of 50 days).

The initial investigation showed that in six cases (85.7%) the clinical picture was prompted by infectious diseases, two of which (33.3%) were secondary to visceral leishmaniasis, three (50%) after infections with Epstein-Barr virus (EBV) and one (16.7%) triggered by cytomegalovirus (Table 2).

Four cases were considered secondary forms: two had visceral leishmaniasis (#1 and #3) and entered into remission after the infection was treated with liposomal amphotericin B but without specific therapy for HLH. The initial clinical picture of the patient with positive serology (IgM) for EBV was severe; he received induction therapy following the HLH94 protocol, and entered into remission after eight weeks (#5). The last patient (#6) had a prior diagnosis of juvenile rheumatoid arthritis and developed HLH secondary to the underlying disease (macrophage activation syndrome) triggered by EBV infection. The child received induction therapy following the HLH2004 protocol and entered into remission after eight weeks. The secondary form cases are currently being followed as outpatients and continue in remission.

After a retrospective review, the other three cases were considered likely to have been primary forms of HLH. Data that contributed to this suspicion were: age at diagnosis (all were infants), no response to immunochemotherapy (in two cases), and in the third case, history of siblings dying with similar clinical presentations.

Two patients (#2 and #4) received immunochemotherapy (Histiocyte Society HLH2004 and HLH94 protocols)2,7,8 and failed to achieve remission after the induction and maintenance phases. The first patient (#2) underwent unrelated allogeneic bone marrow transplantation and responded well. He is currently being followed in the outpatient clinic. After a seven-month follow-up, the second patient (#4) died from severe sepsis of a pulmonary focus with active disease.

The third patient (#7) aged one month and with a family history of death of siblings from rapid infectious complications, died 48 h after admission, presenting with severe sepsis of an unknown etiologic agent before there was enough time to start specific treatment. Results from the autopsy suggested HLH.

Mortality among patients in the study was 28.6% (2/7) and both deaths occurred in patients suspected of having primary HLH.

Discussion

HLH has multifaceted presentations with nonspecific signs and symptoms that are found in other clinical conditions. In the present study the most frequent clinical and laboratory findings at diagnosis were prolonged fever, splenomegaly, and cytopenias, particularly anemia and thrombocytopenia, as has already been described in the literature.3

Hemophagocytosis, the phenomenon that lends its name to the nosological entity, is not a prerequisite for the clinical diagnosis of HLH.6 This phenomenon was observable at some point during the follow-up in all but one case of this series. Nevertheless, absence of hemophagocytosis should not delay the diagnosis when the initial clinical picture fulfills the other criteria.3 This morphological phenomenon can also be induced by other events such as blood transfusion, infection, autoimmune diseases, and some types of bone marrow failure.6

Despite the limited access to more complex laboratory tests, common to many institutions where molecular genetic studies and assessment of NK cell activity and soluble CD256are not available, HLH diagnosis was possible in the seven reported cases because each fulfilled at least five of the eight criteria described by the Histiocyte Society2 The absence of molecular studies, however, prevented confirmation of the diagnosis of primary HLH cases, essential for predicting the risk of recurrence and for defining disease predisposition in asymptomatic family members.6

In this case series, only three patients underwent investigation for changes in the central nervous system (CNS). In two of these cases, the CSF was examined, and pleocytosis was detected in both, with atypical cells present in one. Neurological abnormalities are a prominent feature of this disease. CNS involvement can cause severe and irreversible damage. It is recommended that all patients should be submitted to neurological evaluations with lumbar puncture even when asymptomatic.6,9

Familial HLH is considered an autosomal recessive genetic disorder with an estimated prevalence of 1/50,000 live births. Approximately 70–80% of patients with familial HLH have symptoms in the first year of life.3 Although cases with documented genetic defects are, by definition, primary, infectious processes appear as the trigger in the majority of these children. Because it is a recessive disorder, negative family history is common and results in such cases are wrongly defined as secondary, especially when initial treatment induces satisfactory clinical remission.5 Thus, the use of the terms primary and secondary HLH is not ideal.

In the present study, patients with suspected familial HLH manifested symptoms within the first two years of life. In two cases, a related infectious disease was identified. The patient whose diagnosis was established in the second month of life was the most severe case and rapidly progressed to death. As described in the literature, the younger the patient is at diagnosis, the greater the severity of the presentation.2,6,8

Six cases were related to infections, which also concurs with descriptions in several reviews on the topic.2,4,6,7 According to the Histiocyte Society study HLH94 and many other studies, the most common infectious trigger is the EBV; in these cases, the initial clinical picture is typically severe.6,7,10 However, there are reports that clinical presentation of HLH secondary to EBV infection is very variable, ranging from spontaneously resolved inflammation to extremely severe cases that require immunochemotherapy10 followed by stem cell transplantation.2 Among the patients in this sample who had EBV-related HLH, all had very severe initial clinical presentations and required immunochemotherapy to control signs and symptoms.

In this series, two cases were associated with visceral leishmaniasis. Both achieved HLH remission after the underlying infection was treated and required no anti-inflammatory or cytotoxic therapies, also in agreement with the literature. It is important to note, however, that without treating the underlying infection, the mortality rate is very high.3

Macrophage activation syndrome occurred in one patient previously diagnosed with juvenile rheumatoid arthritis, the autoimmune disease most commonly associated with HLH. The patient initially presented with severe hepatitis and coagulopathy, very common findings in this specific group of patients.3

The immediate goal of treatment of patients with HLH is to suppress the hyperinflammation, responsible for the symptoms that put the patient's life at risk. Thus, chemotherapeutic and/or immunosuppressive agents such as corticosteroids, cyclosporin, and immunoglobulin are used. In familial HLH, the ultimate goal should be stem cell transplantation to substitute the defective immune system with properly functioning effector cells. Without treatment, uncontrolled hyperinflammation leads to persistent neutropenia and death from repeated fungal and bacterial infections or multiple organ failure.4,8

A retrospective review of this series revealed that complete response after immunochemotherapeutic treatment was achieved only in patients with a diagnosis of secondary HLH. Although effective in prolonging the survival of patients with familial HLH, it is known that immunochemotherapy alone cannot cure this form of the disease.6

The mortality rate in our study was 28.6%, lower than the death rate described by the Histiocyte Society, which is around 50%.2,6,7 The number of cases in our series, however, is very small. If we consider that all deaths occurred in patients with primary HLH and of those, only the one who underwent BMT is alive, the data from this study is in agreement with the literature, which gives a 100% mortality rate for patients with primary HLH who are not submitted to BMT3,6,10

Despite the small sample size, test limitations, and the retrospective nature of this study, all of which are factors that prevent more definitive conclusions, the cases presented here demonstrate the importance of raising awareness about HLH among professionals involved in the care of pediatric patients. Access to diagnostic procedures that allow a more definite diagnosis of suspected cases of familial HLH are evidently needed, both for the patient and for conducting family counseling. We should emphasize the need for prospective and cooperative studies in order to enhance understanding about HLH in Brazil, so as to improve its clinical management.

0 Thoughts to “Hlh Case Study

Leave a comment

L'indirizzo email non verrà pubblicato. I campi obbligatori sono contrassegnati *